Oncopeptides: Q4 Sales Below Target - Redeye
Bildkälla: Stockfoto

Oncopeptides: Q4 Sales Below Target - Redeye

Redeye updates its base case based on lower-than-expected Q4 2025 sales and the company's new financial targets.

Redeye updates its base case based on lower-than-expected Q4 2025 sales and the company's new financial targets.
Börsvärldens nyhetsbrev